The essential event in platelet adhesion to the injured blood vessel wall is the binding to sub-endothelial collagen of plasma von Willebrand factor (VWF), a protein which interacts transiently with platelet glycoprotein (GP) Ibα [1] [2] [3] , slowing circulating platelets to facilitate firm adhesion through collagen receptors, including integrin α2β1 and GPVI. To locate the site in collagen that binds VWF, we synthesized 57 overlapping triple-helical peptides comprising the whole triple-helical domain of collagen III. Peptide #23 alone bound VWF, with similar affinity to that of native collagen III. Immobilized peptide #23 supported platelet adhesion under static and flow conditions, processes blocked by an antibody which prevents collagen from binding the VWF A3 domain. Truncated and alanine-substituted peptides derived from #23 either strongly interacted with both VWF and platelets, or lacked both VWF and platelet binding. Thus, we identified the sequence RGQOGVMGF (O is hydroxyproline) as the minimal VWF-binding sequence in collagen III.
Introduction
The interaction of collagen with von Willebrand Factor (VWF) requires unique structural properties in both proteins. Optimal haemostatic function requires multimerisation of up to fifty VWF monomers in circulating plasma; higher-order multimers bind collagen more tightly than smaller assemblies of VWF 4 . Several collagens occur in the vessel wall, of which collagens I and III are considered most important in supporting platelet adhesion to the damaged vasculature 5 . We have identified the residues in the VWF A3 domain that bind collagen III, using sitedirected mutagenesis guided by the crystal structure of the VWF A3 domain in complex with a monoclonal antibody (RU5) that inhibits its interaction with collagen 6, 7 . Nishida et al. mapped the collagen-binding mode of the A3 domain by NMR, and confirmed results by site-directed mutagenesis 8 . However, the VWFbinding site(s) in collagen are unknown, although progress in understanding how collagen interacts with integrin α2β1 and GPVI has been made using short synthetic triple-helical peptide analogues of collagen 9, 10 , including the Collagen III Toolkit
11
.
We used the same approach to identify the high-affinity VWF-binding site in human collagen III, information which may help to develop the collagen-VWF interaction as an anti-thrombotic target 12, 13 .
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Materials and Methods

Peptide synthesis
The synthesis and characterisation of the fifty-seven overlapping triple-helical peptides of the Collagen III Toolkit (Supplementary Table S1 ) is detailed elsewhere 11 .
The same approach was used to synthesise and verify derivative peptides (Supplementary Table S2 ). 16 , and platelet adhesion was evaluated 17 .
Surface plasmon resonance
A Biacore 2000 system (Biacore AB, Uppsala, Sweden) was used for surface plasmon resonance analysis (SPR). Peptides were immobilized on a CM5 sensor chip via the cysteine free thiols in the peptide N-and C-termini, using the manufacturer's procedures. Binding to a channel coated with control peptide, GPC-(GPP) 10 -GPC was used to correct the binding of VWF or A3 domain to collagen-or other peptide-coated channels, and VWF concentration used to calculate affinities was based on that of the monomer, measured by ELISA.
For personal use only. on January 10, 2018. by guest www.bloodjournal.org From A non-helical derivative of peptide #23, flanked by GAP rather than GPP repeats, bound neither VWF nor platelets (data not shown), indicating the same requirement for triple-helical structure for the recognition of collagen by VWF as for α2β1 and GPVI 9, 10 .
Results and Discussion
Mapping the VWF-binding site within collagen III
Identification of the minimal collagen sequence required for VWF binding
A set of truncated triple-helical derivatives of peptide #23 was synthesised, including an alanine-scanned set, peptides 7 -14 (Supplementary Table S2 We previously reported putative VWF-binding sites in collagen III 21 , but VWF bound weakly to these synthetic triple-helical peptides compared with full-length collagen.
These peptides were short stretches of cyanogen bromide fragments of bovine collagen, and so lacked the intact high-affinity binding site, which was cleaved in the parent collagen by cyanogen bromide digestion at the methionine residue within the sequence that we now report.
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The triple-helical peptide GPRGQOGVMGFO at 500µg/ml (~40µM) inhibited binding of VWF, or platelets from whole blood, to immobilized collagen III under flow conditions almost completely ( figure 2D ).
These results confirm the sequence RGQOGVMGF as the major, high-affinity VWFbinding site, and exclude the prominent role for the VWF A1 domain in collagen binding postulated previously 22 . We cannot exclude the possibility that the residual binding of the A3-domain mutant, His1023Ala, reflects weak binding of VWF to
Peptide #23 through A1, nor that binding of A3 is required to render A1 competent to bind collagen at a separate site.
Our data suggest that inhibition of VWF binding to collagen, by peptides, antibodies or other antagonists that target this nonapeptide collagen sequence, may be a useful therapeutic strategy. Current anti-platelet therapy addresses platelet activation through amplification pathways including purinergic receptors and thromboxane generation, or the up-regulation of the fibrinogen receptor integrin α IIb β 3 . Previous use of in vivo models suggested that inhibition of the collagen-VWF interaction with a monoclonal antibody or a naturally-occurring collagen-binding protein, by targeting primary platelet adhesion to the arterial sub-endothelium, has a better risk/benefit ratio than inhibition of platelet-platelet interaction 12, 13 , and might provide a valuable alternative to the anti-platelet therapies in current clinical practice, recently reviewed Table S1 ) were each immobilized on a 96 well plate and the adhesion of plasma-derived VWF (1 µg/ml) was determined. B)
Immobilized peptide #23 was incubated with plasma-derived VWF (1 µg/ml) in presence or absence of monoclonal antibody RU5 (1 µg/ml), or with recombinant wild-type, delta-A3, or His1023Ala VWF (all at 1 µg/ml). In A and B, bound VWF was detected as described in Materials and Methods, and the mean ± SD is shown from a representative of three independent experiments, each performed in duplicate. C) Immobilized peptide #23 or immobilized collagen III (100 µg/ml) were incubated with increasing concentrations of VWF, detected as above. D) Peptide #23 or vehicle (see Figure 2 and Supplementary data, Table S2 ) were immobilized on a 96-well plate, and incubated with plasma-derived VWF (1 µg/ml), and bound VWF was detected as in Figure 1 . B) The same peptides were spray-coated onto Thermanox® coverslips (0.5 µg/cm 2 ), and perfused with whole blood at a shear rate of 300s -1 for 5 minutes, then surface coverage was measured as described for 
